Edison Investment Research - ReNeuron Group (RENE) ReNeuron Group - Differentiating in exosome drug delivery

Report

Edison Investment Research

Sean Conroy

ReNeuron Group - Differentiating in exosome drug delivery

ReNeuron Group, a stem cell-derived exosome technology company, has presented encouraging preclinical data highlighting the enhanced drug delivery capability of its customisable exosome platform (CustomEx) over conventional human embryonic kidney-derived (HEK) exosomes. The company’s CustomEx exosomes displayed a minimum 10-fold increase in cellular uptake across three cell types (endothelial, neural and epithelial) compared to HEK-derived exosomes, with an 18-fold increase observed in endothelial cells. Additionally, when loaded with a therapeutic payload (small interfering RNA, siRNA), a 600% improvement in delivery to the target cell was recorded versus HEK exosomes. The most advanced exosome technologies that have entered clinical development, to date, are HEK-derived exosomes. We believe these results therefore not only provide encouraging signs for the clinical progression of ReNeuron’s exosomes, but may also provide a distinct competitive advantage against HEK competitors. Our estimates are currently under review.

07/10/2022 1 EN

Underlying

ReNeuron Group

Reneuron Group researches and develops therapies using stem cells. Co.'s products include: CTX cells for stroke disability, which is its therapeutic candidate for the treatment of patients left disabled by the effects of a stroke; human retinal progenitor cells (hRPCs) for retinitis pigmentosa (RP), which is its therapeutic hRPC candidate for the treatment of RP, a blindness-causing disease of the retina; hRPCs for cone-rod dystrophy, which is a hRPC therapeutic candidate across a range of genetic diseases of the eye; and CTX-derived exosomes, which is its exosomes nanomedicine platform that generates early pre-clinical data in cancer.

See profile

GB00BF5G6K95 London Stock Exchange United Kingdom

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Sean Conroy

Other Reports on these Companies

Edison Investment Research

ReNeuron Group - Termination of coverage

Edison Investment Research is terminating coverage on ReNeuron Group (RENE). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

March 22, 2024 March 22, 2024 1 EN

Hardman & Co

Hardman & Co Healthcare Index: 2023 – Capital demands dent performance

The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the second year running, apart from global economic influences affecting world markets, performance in 2023 was dented by the capital-intensive nature of the sector. The HHI fell 3.7%, to 483.8, underperforming the main London markets – FTSE 100 (+3.8%) and FTSE All-Share (3.8%) but outperforming the FTSE AIM All-Share Index (-8.2%). Only 15 companies in our index saw share prices rise in 2023, four of these benefiting from ...

January 12, 2024 January 12, 2024 1 EN

EQS Group AG

Edison issues update on ReNeuron Group (RENE): H124 results reaffirm focus on CustomEX™

Edison Investment Research Limited Edison issues update on ReNeuron Group (RENE): H124 results reaffirm focus on CustomEX™ 27-Nov-2023 / 08:53 GMT/BST The issuer is solely responsible for the content of this announcement. London, UK, 27 November 2023 Edison issues update on ReNeuron Group (RENE): H124 results reaffirm focus on CustomEX™ ReNeuron has announced its H124 results (to end-September 2023), reaffirming its commitment to advance CustomEX™, its proprietary stem cell-derived exosome delivery platform. The key operational update from the period included in vivo data...

November 27, 2023 November 27, 2023 1 EN

On the Beach Group - Feeling festive

The increase of 22% in booked total transaction value (TTV) both in H124 and for this summer, driven by successful expansion into premium and long haul and backed by its pioneering perks, confirm On the Beach’s (OTB’s) progress in addressing a market it estimates to be 5x more valuable than its core Value (3*) business (now just 25% of bookings) as well as more dynamic. Another ‘very big deal’ for OTB is its new ‘transformational’ partnership with Ryanair, its most significant low-cost carrier, ensuring free and fair access to seat supply and marking a more positive relationship, given outstan...

May 24, 2024 May 24, 2024 1 EN

Alison Turner

Alison Turner

Pan African Resources - An accounting storm in a legal teacup

This morning, Pan African announced that it may have been in technical breach of the net asset test when it paid out dividends to shareholders in the five years from FY19–23 and also when it instigated its share buyback programme in 2022. As attested to by the fact that it took five years to be noticed, the apparent breach arises from the nexus of an arcane bit of legislation and a curious distinction between the presentation currency of the group (the US dollar) and its functional currency (the South African rand) and the effect of the depreciation of the latter against the former on the dist...

May 24, 2024 May 24, 2024 1 EN

Sean Conroy

Sean Conroy

Cereno Scientific - All eyes on Q3 readout after Q1 update

Cereno Scientific’s Q124 results provided a financial update and recapped the company’s clinical plans and progress. The Phase II trial for lead asset CS1 (pulmonary arterial hypertension, PAH) remains on track for a Q324 readout and we expect the Expanded Access Program approved by the FDA in January 2024 will help Cereno build a more robust data package for the subsequent Phase IIb/III trial. Additionally, the clinical trial application (CTA) submission for CS014 to the EMA in April 2024 brings a second asset to the clinic, bolstering the company’s clinical pipeline. We believe Cereno’s liqu...

May 24, 2024 May 24, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

ReNeuron Group - Differentiating in exosome drug delivery

ReNeuron Group - Termination of coverage

Hardman & Co Healthcare Index: 2023 – Capital demands dent performance

Edison issues update on ReNeuron Group (RENE): H124 results reaffirm focus on CustomEX™

On the Beach Group - Feeling festive

Pan African Resources - An accounting storm in a legal teacup

Cereno Scientific - All eyes on Q3 readout after Q1 update

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe